In vitro and in vivo biopharmaceutical evaluation of Lorazepam commercial tablets [Valutazione biofarmaceutica in vitro e in vivo di compresse commerciali di Lorazepam]

In vitro and in vivo biopharmaceutical evaluation of Lorazepam commercial tablets Objective. Lorazepam (LZM) is a broadly used tranquillizer for the treatment of anxiety. Tavor® is one of the most diffused registered drug products containing LZM. Lots of generic drug products containing LZM have been registered in Italy by several pharmaceutical groups and are present in the Italian market. Due to the wide medical prescription of products containing LZM, it seemed interesting, from a technological and biopharmaceutical point of view, to perform a comparative bioequivalence evaluation of a trade marked and generic tablet formulations containing LZM available in the Italian market. Materials and Methods. The trial vas carried out on four preparations, including Tavor® (1 mg) as reference product and three generics named A, B and C. In vitro technological parameters (dissolution, uniformity of content, uniformity of weight) and in vivo (pharmacokinetic on rabbit) studies were performed. Results. All the examined brands passed technological tests according the European Pharmacopeia 5th ed. and USP25. Tavor® ensures a faster dissolution behaviour than the tree generics in vitro. All the pharmacokinetic parameters were within the prescriptions of EMEA, even if the reference product showed the highest values of AUC0-∞ and of Cmax. Conclusions. Obtained results show that Tavor® ensures a faster dissolution behaviour than the tree generics in vitro. Moreover, considering the pharmacokinetic data, it is possible to suppose that the generics B and C are not able to provide the same therapeutic effect as the reference product.